Can BCR/ABL breakpoint fusion peptides be used as a target for GVL immunotherapy by expanding peptide specific T cells in patients in vivo?

Authors
Publication date
1 January 2004
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Sustaining member

    Nottingham Trent Institutional Repository (IRep)

    redirect
    oaioai:irep.ntu.ac.uk:7819
    Last time updated on 14/03/2016